Risk of bleeding not increased by sorafenib or sunitinib
- PMID: 20152763
- DOI: 10.1016/S1470-2045(09)70366-3
Risk of bleeding not increased by sorafenib or sunitinib
Comment on
-
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.Lancet Oncol. 2009 Oct;10(10):967-74. doi: 10.1016/S1470-2045(09)70222-0. Epub 2009 Sep 18. Lancet Oncol. 2009. PMID: 19767240
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
